Science AI Journal
Biochemistry, Genetics and Molecular Biology · Research topic

Open research questions in Breast Cancer Treatment Studies

771 gap statements mined from Breast Cancer Treatment Studies papers in our 7.9M-paper local library, which holds 4,043 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Breast Cancer Treatment Studies? See the ranked Biology journals.

What the literature leaves open

  • Current guidelines provide limited recommendations for biomarker-guided treatment adaptation after receptor change. The clinical implications of receptor conversion remain uncertain.

    Clinical Decision-Making After Receptor Conversion Following Neoadjuvant Therapy in Breast Cancer: A Three-Strategy Framework · 2026 · DOI

  • The study identifies the challenge of limited treatment options for TNBC. The study identifies the challenge of high risk of recurrence in TNBC. The study identifies the challenge of lack of effective specific targeted therapy for TNBC.

    Antibody-drug conjugates therapy for triple-negative breast cancer: a systematic review and meta-analysis · 2026 · DOI

  • Lack of epidemiological data on early-onset breast cancer in low- and middle-income countries. Limited understanding of the clinical and demographic profiles of early-onset breast cancer patients.

    Early-onset breast cancer in two Brazilian tertiary cancer centers: a real-world study of years of life lost and clinical outcomes · 2026 · DOI

  • The KEYNOTE-522 trial did not directly compare neoadjuvant with adjuvant chemo-immunotherapy. Adjuvant-only immune checkpoint inhibitor (ICI) strategies have not demonstrated consistent improvement in their primary efficacy endpoints in TNBC.

    Neoadjuvant Versus Adjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer: A National Cancer Database Study · 2026 · DOI

  • Further functional studies are warranted to validate CDC25A as a potential prognostic and therapeutic biomarker in breast cancer.

    Insights into the prognostic significance of cell division cycle 25A (CDC25A) in breast cancer · 2026 · DOI

  • As a pivotal calcium release channel on ER, ITPR3 is speculated to participate in endoplasmic reticulum stress and paraptosis execution, but its diagnostic value and regulatory role in TNBC have not been systematically elucidated.

    Integrated single-cell and bulk RNA sequencing analysis reveals paraptosis-related biomarkers and immune microenvironment regulation in triple-negative breast cancer · 2026 · DOI

  • While Single Nucleotide Polymorphisms (SNPs) have been linked to fibrosis after radiotherapy (RT), the genetic architecture remains incompletely understood.

    A genome-wide association study on radiation induced fibrosis in breast cancer patients · 2026 · DOI

  • Although limited randomized and retrospective data suggest that this approach may suit a subset of patients, its role remains uncertain.

    Outcomes of Technically Optimal Intraoperative Radiation Therapy With Electrons Versus Whole-Breast External Beam Radiation in Suitable Patients With Breast Cancer · 2026 · DOI

  • The incremental clinical value of trajectory classification over the simpler D7 drainage measurement remains uncertain and requires prospective validation.

    Association of drainage volume decline trajectories during the first 7 postoperative days with persistent seroma on postoperative day 30 after modified radical mastectomy for breast cancer · 2026 · DOI

  • However, due to the limitations of this study, we are only doing preliminary exploration for information, and do not make any causal inference.

    Exploring the relationship between transferrin and progression-free survival in breast cancer patients after neoadjuvant therapy · 2026 · DOI

  • Despite its potential as both a prognostic biomarker and a therapeutic target in triple-negative breast cancer (TNBC), the exact role of TEM8 in TNBC remains poorly understood.

    Expression and clinical significance of TEM8 protein in triple-negative breast cancer · 2026 · DOI

  • The prognostic relevance of multifocal and multicentric breast cancer remains unclear and current staging systems do not consider focality.

    Comparing multifocal with unifocal breast cancer and the relationship with survival: national cohort study · 2026 · DOI

  • The relationship between routine histopathological features, immune infiltration, and genomic risk within this framework remains incompletely characterized in luminal disease.

    Tumour-infiltrating lymphocytes differ across MammaPrint® classifications in breast cancer · 2026 · DOI

  • Breast cancer incidence increases with age, but the molecular features of cancers arising in older patients remain poorly characterized.

    A Multi-Cohort Analysis of Age-Associated Clinical and Transcriptomic Differences in Breast Cancer · 2026 · DOI

  • However, the role of leptin in the molecular heterogeneity of triple-negative breast cancer (TNBC), particularly across racial groups, remains unclear.

    Leptin-Driven Distinct Transcriptional Reprogramming in Triple-Negative Breast Cancer: Implications for Racial Disparities · 2026 · DOI

  • As accelerated partial breast irradiation is gaining widespread acceptance for low-risk breast cancers treated with breast conservation, its role following oncoplastic surgery remains controversial.

    Phase 2 Trial of Ultrahypofractionated Image-guided Partial Breast Irradiation Following Lumpectomy with Optional Oncoplastic Reconstruction for Early-stage Breast Cancer · 2025 · DOI

  • New strategies that improve locoregional control rates in BLIS patients are warranted.

    Novel Molecular Subtyping Predicts Locoregional Recurrence in Triple-negative Breast Cancer · 2025 · DOI

  • Further adequate baseline data on LIV1 expression in other populations have not been documented.

    Expression of cell surface zinc transporter LIV1 in triple negative breast cancer is an indicator of poor prognosis and therapy failure · 2024 · DOI

  • Future studies are required to identify patients with ILC who are at risk of late recurrence or mortality.

    Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast · 2024 · DOI

  • Emerging data indicate that host factors may impact the SME, but the relationship between prediagnostic host factors and SME phenotype remains poorly characterized, particularly among women of African ancestry.

    Contribution of Prediagnostic Host Factors to Shaping the Stromal Microenvironment of Breast Cancer among Sub-Saharan African Women · 2024 · DOI

  • However, community-level variability remains unknown, and research regarding the association between testing status and receipt of adjuvant chemotherapy is limited.

    Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities? · 2024 · DOI

  • No standardized staging, pathology reporting protocol, or consensus classification exists within current frameworks.

    Residual Pure Intralymphatic Breast Carcinoma After Neoadjuvant Therapy: Clinicopathologic Analysis and Comparative Outcomes Across Published Studies · 2026 · DOI

  • Limited to a nationwide cross-sectional survey in Poland, - Survey responses may not reflect actual clinical practice, - No direct evidence is available for most receptor-conversion…

    Clinical Decision-Making After Receptor Conversion Following Neoadjuvant Therapy in Breast Cancer: A Three-Strategy Framework · 2026 · DOI

  • In summary, these findings identify circulating ETP as a potential biomarker in ER+ metastatic breast cancer and support further investigation of its relationship with disease activity and the development of ETP-targeting agents.

    Endotrophin Is a Circulating Fibroinflammatory Biomarker Associated with Treatment Response in Human Metastatic ER+ Breast Cancer · 2026 · DOI

  • Further studies are needed to confirm the findings, - Research on the optimal treatment strategy for early-stage triple-negative breast cancer, - Investigation of the factors associated with neoadjuvant treatment, - Analysis of the cost-effectiveness of neoadjuvant…

    Neoadjuvant Versus Adjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer: A National Cancer Database Study · 2026 · DOI

Most-cited papers in Breast Cancer Treatment Studies

Most recent work

Find a gap in your own Breast Cancer Treatment Studies sub-topic

This page shows what the Breast Cancer Treatment Studies literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Biochemistry, Genetics and Molecular Biology

Gut microbiota and health
4,284 open questions
Extracellular vesicles in disease
1,862 open questions
Antibiotic Resistance in Bacteria
1,778 open questions
Inflammatory Bowel Disease
1,518 open questions
RNA modifications and cancer
1,209 open questions
Single-cell and spatial transcriptomics
1,178 open questions
Genetic Associations and Epidemiology
1,146 open questions
Epigenetics and DNA Methylation
1,090 open questions
Open questions raised by papers listed on this page include: (1) The study identifies the challenge of lack of effective specific targeted therapy for TNBC (“Antibody-drug conjugates therapy for triple-negative breast cancer: a…”, 2026); (2) Lack of epidemiological data on early-onset breast cancer in low- and middle-income countries (“Early-onset breast cancer in two Brazilian tertiary cancer centers: a…”, 2026); (3) Further functional studies are warranted to validate CDC25A as a potential prognostic and therapeutic biomarker in breast cancer (“Insights into the prognostic significance of cell division cycle 25A (CDC25A)…”, 2026); (4) As a pivotal calcium release channel on ER, ITPR3 is speculated to participate in endoplasmic reticulum stress and paraptosis execution, but its diagnostic value and regulatory role in TNBC have not been systematically elucidated (“Integrated single-cell and bulk RNA sequencing analysis reveals…”, 2026); (5) While Single Nucleotide Polymorphisms (SNPs) have been linked to fibrosis after radiotherapy (RT), the genetic architecture remains incompletely understood (“A genome-wide association study on radiation induced fibrosis in breast cancer…”, 2026). 771 gap statements have been mined from Breast Cancer Treatment Studies papers in our 7.9M-paper local library, which holds 4,043 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.